Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NGR-hTNF + Best Investigator's Choice
- Development stage
- Discontinued
- Lead developer
- AGC Biologics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
NGR-hTNF is a recombinant fusion protein consisting of human tumor necrosis factor alpha (hTNF-α) linked to the NGR (asparagine-glycine-arginine) peptide. The NGR peptide selectively targets the CD13 (aminopeptidase N) isoform expressed on the neo-vasculature of tumors. By delivering low doses of TNF-α specifically to the tumor environment, it alters vascular permeability and the tumor microenvironment, thereby enhancing the penetration of co-administered chemotherapeutic agents and promoting T-cell infiltration. In the context of malignant pleural mesothelioma, it was evaluated in combination with Best Investigator's Choice (BIC), which included single-agent doxorubicin, gemcitabine, or vinorelbine. Although the Phase III NGR015 trial did not meet its primary endpoint, the drug demonstrated a favorable safety profile.
- Other names
- NGR-human Tumor Necrosis FactorNGR-hTNF plus Best Investigator's Choice
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TNFR2 (Tumor necrosis factor receptor superfamily member 1B)ANPEP (Aminopeptidase N)
Beyond the preview
Go deeper on NGR-hTNF + Best Investigator's Choice.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGR-hTNF + Best Investigator's Choice.